Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TECH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Litigation (new) — A shareholder lawsuit alleges the merger proxy statement misrepresented or omitted material information and seeks to enjoin the shareholder vote.
Bio-Techne supplements merger proxy after shareholder lawsuit alleges omissions
Filed September 14, 2026 · Period ending September 14, 2026 · ~1 min read
Key Changes
-
high
A shareholder lawsuit filed September 9, 2026 alleges the merger proxy misrepresented or omitted material information and seeks to enjoin the September 23 vote.
Item 8.01 verify on EDGAR → -
high
Bio-Techne denies the allegations but is voluntarily supplementing proxy disclosures to avoid delay and litigation risk.
Item 8.01 verify on EDGAR → -
medium
Supplemental disclosures include Merck KGaA's 2023 verbal interest at $92-$95 per share when the stock traded between $73.76 and $85.98.
Item 8.01 verify on EDGAR → -
medium
Additional details cover Goldman Sachs' valuation inputs: ~$200M debt, ~$210M cash, and other balance sheet items.
Item 8.01 verify on EDGAR → -
medium
The supplement clarifies no post-closing employment arrangements were discussed between Bio-Techne executives and Merck KGaA from July 2025 until the merger agreement.
Item 8.01 verify on EDGAR →
Summary
Bio-Techne is facing a shareholder lawsuit over its merger proxy statement. The suit, filed September 9, 2026 in Minnesota state court, alleges the proxy misrepresented or omitted material information and seeks to block the September 23 shareholder vote on the Merck KGaA merger. Bio-Techne says the claims are without merit but is voluntarily supplementing the proxy disclosures to avoid delay and litigation risk.
The supplemental disclosures add detail on Merck KGaA's 2023 verbal interest at $92-$95 per share, Goldman Sachs' valuation inputs including approximately $200 million in debt and $210 million in cash, and confirmation that no post-closing employment arrangements were discussed between Bio-Techne executives and Merck KGaA from July 2025 until the merger agreement was signed.
Multiple shareholders also sent demand letters alleging deficient disclosures, which Bio-Techne denies. For retail holders, the lawsuit and supplemental disclosures are material because they could affect the timing or outcome of the merger vote. The added background on prior interest and valuation inputs gives shareholders more context to evaluate the deal, but the litigation itself introduces uncertainty around the September 23 vote.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Bio-Techne supplements merger proxy disclosures after shareholder lawsuit and demand letters allege omissions.
Added in current filing · verify on EDGAR →
The Lawsuit was filed by a purported Bio-Techne shareholder and alleges claims under Minnesota statutory and common law contending, among other things, that the Proxy Statement misrepresented or omitted material information.
A purported shareholder filed suit against Bio-Techne, its directors, Merck KGaA, Darmstadt, Germany, and Merger Sub, seeking to enjoin the September 23, 2026 shareholder vote on the merger. Bio-Techne believes the allegations are without merit but is voluntarily supplementing proxy disclosures to avoid delay.
Added in current filing · verify on EDGAR →
multiple purported shareholders of Bio-Techne have delivered demand letters to Bio-Techne (collectively, the “Demand Letters”), alleging that the disclosures contained in the Proxy Statement are deficient in certain respects.
Several shareholders sent demand letters claiming the proxy statement disclosures are deficient. Bio-Techne denies the allegations and states the disclosures comply fully with applicable law, but is supplementing them to avoid nuisance, risks, costs, and uncertainties.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 15, 2026 · How we verify